Skip to Content Skip to Search

Our pipeline

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.

 

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

 

The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.

 

For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

 

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

 

This information was updated on 23 June 2021.

 

For COVID-19 vaccines, GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations.

Download full pipeline in XLSX

XLSX - 25.1KB

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
‡
Ph2 study start imminent
§
Potentially Registrational Ph2
*
In a Phase 1/2 study
#
transition activities underway to enable further progression by external partner

Pipeline updated 23 June 2021

  • Additional indication
  • Immuno-modulator

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
‡
Ph2 study start imminent
§
Potentially Registrational Ph2
*
In a Phase 1/2 study
#
transition activities underway to enable further progression by external partner

Pipeline changes to be published at Q2 2021

Key

†
In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
‡
Ph2 study start imminent
§
Potentially Registrational Ph2
*
In a Phase 1/2 study
#
transition activities underway to enable further progression by external partner
  • Additional indication
  • Immuno-modulator

No results - Please try with another term

    

Quick Links

Find out more